PharmaSGP Holding SE (PSG.DE)
EUR 24.8
(4.2%)
EUR 24.8
(4.2%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 73.97 Million EUR | 733.17% |
| 2022 | 8.87 Million EUR | -89.58% |
| 2021 | 85.19 Million EUR | 22085.94% |
| 2020 | 384 Thousand EUR | 51.18% |
| 2019 | 254 Thousand EUR | -49.8% |
| 2018 | 506 Thousand EUR | -23.33% |
| 2017 | 660 Thousand EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 728 Thousand EUR | -99.02% |
| 2024 Q1 | 74.01 Million EUR | 0.05% |
| 2023 Q4 | 73.97 Million EUR | 7246.28% |
| 2023 Q1 | 1.12 Million EUR | -87.39% |
| 2023 Q2 | 1.01 Million EUR | -9.02% |
| 2023 FY | 73.97 Million EUR | 733.17% |
| 2023 Q3 | 1 Million EUR | -1.18% |
| 2022 Q3 | 1.29 Million EUR | -8.84% |
| 2022 Q1 | 113 Thousand EUR | -99.87% |
| 2022 FY | 8.87 Million EUR | -89.58% |
| 2022 Q4 | 8.87 Million EUR | 583.53% |
| 2022 Q2 | 1.42 Million EUR | 1161.06% |
| 2021 Q2 | 360 Thousand EUR | -18.0% |
| 2021 FY | 85.19 Million EUR | 22085.94% |
| 2021 Q4 | 85.19 Million EUR | 30435.48% |
| 2021 Q3 | 279 Thousand EUR | -22.5% |
| 2021 Q1 | 439 Thousand EUR | 14.32% |
| 2020 Q1 | - EUR | -100.0% |
| 2020 FY | 384 Thousand EUR | 51.18% |
| 2020 Q4 | 384 Thousand EUR | -8.57% |
| 2020 Q3 | 420 Thousand EUR | -12.68% |
| 2020 Q2 | 481 Thousand EUR | 0.0% |
| 2019 FY | 254 Thousand EUR | -49.8% |
| 2019 Q1 | - EUR | 0.0% |
| 2019 Q4 | 254 Thousand EUR | 0.0% |
| 2018 FY | 506 Thousand EUR | -23.33% |
| 2017 FY | 660 Thousand EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| MPH Health Care AG | 13.05 Million EUR | -466.68% |
| Apontis Pharma AG | 6 Million EUR | -1132.95% |
| Dermapharm Holding SE | 1.08 Billion EUR | 93.153% |
| Evotec SE | 626.19 Million EUR | 88.186% |
| MERCK Kommanditgesellschaft auf Aktien | 9.94 Billion EUR | 99.256% |
| SynBiotic SE | 3.68 Million EUR | -1910.106% |